SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5, version 2.0. Lyon, France: IARC Press, 2004.
  • 2
    EbleJ, SauterG, EpsteinJI, SesterhennIA, editors. Classification of tumours. Pathology and genetics of the tumours of the urinary system and male genital organs. Lyon: World Health Organization, 2004.
  • 3
    Black PC, Brown GA, Dinney CPN. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009; 27: 37.
  • 4
    Mai KT, Park PC, Yazdi HM, Saltel E, Erdogan S, Stinson WA, Cagiannos I, Morash C. Plasmacytoid transitional cell carcinoma. Report of seven new cases. Eur Urol 2006; 50: 11111114.
  • 5
    Fritsche HM, Burger M, Denzinger S, Legal W, Goebell PJ, Hartmann A. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol 2008; 180: 19231927.
  • 6
    Gaafar A, Garmendia M, de Miguel E, Velasco V, Ugalde A, Bilbao FJ, de Petris G, López JI. Carcinoma urothelial plasmocitoide de vejiga urinaria. Estudio de 7 casos. Actas Urol Esp 2008; 32: 806810.
  • 7
    Nigwekar P, Tamboli P, Amin MB, Osunkoya AO, Ben-Dor D, Amin MB. Plasmacytoid urothelial carcinoma detailed analysis of morphology with clinopathologic correlation in 17 cases. Am J Surg Pathol 2009; 33: 417424.
  • 8
    Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005; 23: 49634974.
  • 9
    Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stöhr R, Simon R, Sauter G, Leibiger H, Essers L, Weber B et al. Loss of SFRP1 is associated with breast cancer progression in early stage tumors. Int J Oncol 2004; 25: 6419.
  • 10
    Schwarz S, Rechenmacher M, Filbeck T, Knuechel R, Blaszyk H, Hartmann A, Brockhoff G. Value of multicolor fluorescence in situ hybridization (UroVysion) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 2008; 61: 272277.
  • 11
    Wojcik EM, Brownlie RJ, Bassler TJ, Miller MC. Superficial urothelial (umbrella) cells. A potential cause of abnormal DNA ploidy results in urine specimens. Anal Quant Cytol Histol 2000; 22: 411415.
  • 12
    Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MM, Jenkins RB. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 1996; 149: 11931199.
  • 13
    van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005; 11: 77437748.
  • 14
    Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes 2009; 2: 66.
  • 15
    Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasias and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62: 809818.
  • 16
    Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. Int J Urol 2008; 15: 314318.
  • 17
    Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007; 51: 15260.
  • 18
    Nakai Y, Nonomura N, Kawashima A, Mukai M, Nagahara A, Nakayama M, Takayama H, Nishimura K, Okuyama A. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer. Jpn J Clin Oncol 2010; 40: 2527.
  • 19
    Van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumors. Eur Urol 2007; 52: 760768.
  • 20
    Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Miyake M, Fujimoto K, Hirao K, Konishi N. Role of syndecan-1 (CD138) in cell serviva of human urothelial carcinoma. Cancer Sci 2010; 101: 15560.
  • 21
    Natkunam Y, Warnke RA, Montgomery K, Falini B, Van de Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686694.
  • 22
    Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I, Miura K, Harada S, Kikuchi M, Komatsu H, Banno S, Wakita A et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14: 44956.
  • 23
    Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, Pacini R, Alunni C, Natali-Tanci L, Ugolini B, Sebastiani C, Cattoretti G et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 208492.
  • 24
    Takeichi M. Cadherin cell adheasion receptors as a morphogenetic regulator. Science 1991; 251: 14511455.
  • 25
    Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Depruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 32415.
  • 26
    Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long term follow up. J Urol 2001; 165: 14731479.
  • 27
    Katsuaki Satoa, Yoshimichi Uedaa, Kenji Kawamurab, Kinue Aiharab, Shogo Katsuda Plasmacytoid urothelial carcinoma of the urinary bladder: a case report and immunohistochemical study. Pathol Res Pract 2009; 205: 189194.
  • 28
    Koksal IT, Ates M, Danisman A, Sezer C, Ciftcioglu A, Karpuzoglu G, Sevuk M. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res 2006; 12: 139.
  • 29
    Sun W, Herrera GA. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 2002; 33: 9961000.
  • 30
    Kashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007; 14: 78994.
  • 31
    Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int 2008; 81: 3204.
  • 32
    Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DM, Jankowski JA. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 2008; 215: 18494.
  • 33
    Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 mutations in breast cancer may have important prognostic value. Proc Natl Acad Sci USA 1996; 93: 10936.
  • 34
    Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J. Comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008; 47: 600607.
  • 35
    Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a metaanalysis and review. Lancet Oncol 2005; 6: 678686.
  • 36
    Van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21: 19121921.
  • 37
    Knowles MA. Role of FGFR3 in urothelial carcinoma: biomarker and potential therapeutic target. World J Urol 2007; 25: 581593.
  • 38
    Van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009; 55: 650657.
  • 39
    Karakas B, Bachman KE, Park BH. Mutations of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 455459.
  • 40
    López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A. PIK3CA mutations are an early genetic alterations associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66: 74017404.
  • 41
    Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J. Chromosomal alterations detected by fluorescence in situ hybridisation in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 2008; 130: 552559.